Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Alimentary Pharmacology & Therapeutics|August 19, 2011
Increasing insulin resistance is associated with increased severity and prevalence of gastro-oesophageal reflux diseaseC-S Hsu, P-C Wang, J-H Chen, et al.
Alimentary Pharmacology & Therapeutics|November 9, 2012
Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinomaH-S Shiah, C-Y Chen, C-Y Dai, et al.
Oncogene|April 4, 2017
Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancerJ Jen, L-L Lin, F-Y Lo, et al.
Oncogene|August 18, 2015
Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancerJ Jen, L-L Lin, H-T Chen, et al.
Oncogene|June 20, 2017
Oncoprotein ZNF322A transcriptionally deregulates alpha-adducin, cyclin D1 and p53 to promote tumor growth and metastasis in lung cancerJ Jen, L-L Lin, F-Y Lo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 18, 2015
Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)M De Santis, P J Wiechno, J Bellmunt, et al.
British Journal of Cancer|April 24, 2014
A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignanciesC-C Lin, W-C Su, C-J Yen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 17, 2018
Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancerD E Gerber, L Horn, M Boyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 31, 2020
Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysisV A Papadimitrakopoulou, T S Mok, J-Y Han, et al.
ESMO Open|May 4, 2023
A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancerG Galffy, I Lugowska, E V Poddubskaya, et al.
Pageof 7